Advanced cell programming

An extensive cell programing capability

Engineered T cell immunotherapy products show significant efficacy for hematological malignancies

However, realization of the potential of this approach across a broad range of tumor types will require multiple technology solutions to address limitations of the current generation of therapies.

Our technological approach is the development of advanced T-cell engineering components designed to directly address clinical challenges. A focus in our early stage pipeline is incorporation of multiple components in a single product.

Latest Abstracts & Publications

See all
UCL
December 12 2022

Dual Antigen Targeting with Co-Transduced CD19/22 CAR T Cells May Prevent Antigen-Negative Relapse after CAR T Cell Therapy for Relapsed/Refractory ALL (AUTO1/22)

Obe-cel
AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING
December 12 2022

First in Human Study of AUTO4, a TRBC1-Targeting CAR T-Cell Therapy in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma

AUTO4
AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING
December 11 2022

Safety, Efficiency and Long-Term Follow-up of AUTO1, a Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia (B-ALL) and Other B-Cell Malignancies

Obe-cel